baber/WOPTO huggingface dataset:
Patent JP-2854129-B2 (JP)
IPC: B01J27/08
Filed: 1990-04-03
Granted: 1999-02-03
Abstract: Olefins which are free of allylic hydrogens, and which contain two hydrogens bonded to a carbon atom which is bonded to another carbon by a double bond, from aldehydes when reacted with oxygen in the presence of an acidic silver catalyst, such as silver dispersed on gamma -alumina. For example, 1,3-butadiene is oxidized to crotonaldehyde.
Patent JP-4040101-B2 (JP)
IPC: A23L7/20
Filed: 1997-07-23
Granted: 2008-01-30
Abstract: Process for the preparation of malted cereals, wherein the steeping step includes one or more wetting stages at a temperature between 5 and 30° C. preferably between 10 and 20° C., until the material has a moisture content between 20 and 60% by weight, preferably between 38 and 47%, wherein after a germination period between 2 and 7 days, preferably between 3 to 6 days at a temperature between 10 and 30° C., preferably between 14 and 18° C., the steeped and germinated cereals are preferably kilned by increasing the temperature to values between 40 and 150° C. until the material has a moisture content between 2 and 15% by weight, and wherein one or more microbial cultures selected from the group consisting of one or more bacteria and/or one of more activated spores are added in one or more times during the process.
Patent JP-2628498-B2 (JP)
IPC: H02K49/10
Filed: 1988-07-08
Granted: 1997-07-09
Abstract: PCT No. PCT/EP88/00616 Sec. 371 Date Jun. 20, 1989 Sec. 102(e) Date Jun. 20, 1989 PCT Filed Jul. 8, 1988 PCT Pub. No. WO89/02184 PCT Pub. Date Mar. 9, 1989.A non-contacting linear drive includes a fixed guidance part constructed as a profile part whose magnetic material in the vicinity of helixes (3,4) approaches (8,11,17) the latter and, at a distance from the helixes, forms a return path to the next helix. The rotary part has spaced double helixes, (3,4), a constant magnetic field (7) being produced in the magnetic circuit formed by a double helix and the magnetic return path. A very simple and economic construction and manufacture are consequently possible. The guidance part (2) can be constructed as a profile rail (9) or as a tube (10,15) and has window-like recesses (6), corrugations (11,12) or ribs (17). The double helix (1) can be constructed with permanent magnets (14) placed in the helixes with radial orientation or with permanent magnets (14) provided between soft magnetic helixes in axial orientation.
Patent JP-4316015-B2 (JP)
IPC: B29D5/10
Filed: 1997-08-14
Granted: 2009-08-19
Abstract: A plastic bag comprises first and second opposing panels, a reclosable zipper (22), and a slider (32). The first and second opposing panels (12,14) are fixedly connected to each other along a pair of sides (16) and a bottom bridging the pair of sides. The reclosable zipper extends along a mouth (10) formed opposite the bottom. The zipper (22) includes a first track with a first profile (24) and a second track with a second profile (28). The first and second profiles are releasably engageable to each other. The slider (32) is slidably mounted to the zipper for movement between a closed position and an open position. The first and second profiles (24,28) are engaged to each other while the slider (32) is in the closed position, and the first and second profiles (24,28) are disengaged from each other in response to movement of the slider (32) from the closed position to the open position. To prevent the slider from going past the ends of the zipper and to provide adequate end strength that resists stresses applied to the profiles during normal use of the bag, end stops (36) in the form of flexible segments severed from a flexible plastic strip, fairly rigid segments severed from an extruded clip profile, or softened plastic material, are applied and secured to opposite ends of the zipper.
Patent JP-3682064-B2 (JP)
IPC: B29C48/405
Filed: 1994-11-11
Granted: 2005-08-10
Abstract: The invention relates to a multiscrew, continuous mixing machine for plasticizable compounds with two screws, which rotate in a housing and which penetrate the cylindrical part of the housing that envelops the screw concerned and exhibit feed and metering sections and inbetween at least one homogenizing section and a mixing section, whereby the feed and metering sections are formed by intermeshing conveying screws, which rotate in the same direction and are arranged in the mixing elements, which are opposite the homogenizing and mixing sections and whose edges travel past each other with little clearance while rotating, whereby to form a chamber extending above the mixing elements, the edges maintain a distance from the part of the housing enveloping said edges that is significantly greater than the clearance. The mixing elements comprise process screw elements, whose lengths are in essence identical and which exhibit such a pitch that within the chamber the one process screw element feeds forward and the other process screw element feeds backward.
Patent JP-3807680-B2 (JP)
IPC: C07C19/08
Filed: 1995-10-25
Granted: 2006-08-09
Abstract: PCT No. PCT/EP95/04192 Sec. 371 Date Jun. 25, 1996 Sec. 102(e) Date Jun. 25, 1996 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/13474 PCT Pub. Date May 9, 1996The invention is drawn to a process for the conversion of primary and secondary alcohols into the corresponding fluorine compounds in the presence of an organic solvent, 2-3 equivalents of a strong base and perfluoroalkylsulphonyl fluorides, such as perfluorobutanesulphonyl fluoride or higher homologues.
Patent JP-2855594-B2 (JP)
IPC: A61K8/14
Filed: 1991-09-24
Granted: 1999-02-10
Abstract: The invention relates to a lipid particle forming matrix, characterized by, that from a defined system of at least two lipid components chosen from classes of different polarity, in which at least one of the lipid components is bilayer forming, discrete lipid particles are formed spontaneously when interacting with aqueous systems. Preferably at least one of the lipid components is amphiphatic and polar and one is nonpolar. These discrete particles are formed spontaneously from the matrix without any chemical or physical treatment or initiation. The lipid particle forming matrix can contain bioactive materials, chosen from the group of drugs, herbicides, pesticides, fertilizers, food and cosmetic ingredients or additives. The invention also relates to a process for the production of the matrix, the use of the lipid particle forming matrix as a carrier system for bioactive materials and pharmaceutical composition such as oral, rectal, nasal, vaginal, ocular or parenteral vehicles, creams, ointments, capsules and tablets containing the said lipid particle forming matrix and a drug.
Patent JP-3459011-B2 (JP)
IPC: A61K47/34
Filed: 1991-10-15
Granted: 2003-10-20
Abstract: PCT No. PCT/SE91/00690 Sec. 371 Date Apr. 16, 1993 Sec. 102(e) Date Apr. 16, 1993 PCT Filed Oct. 15, 1991 PCT Pub. No. WO92/06679 PCT Pub. Date Apr. 30, 1992.A melt granulating method for the production of pellets (spheres) which contain a therapeutically active substance of high-dosage type. The method is characterized by: (i) mechanically working a mixture which contains (a) the active substance in cohesive form and (b) a binder (melting point 40 DEG  C.-100 DEG  C.) while supplying sufficient energy for the binder to melt and to form spherical overwetted pellets; (ii) adding further cohesive substance, while maintaining the mechanical working; (iii) interrupting the mechanical working and supply of energy and cohesive substance when the desired mean particle size of dry pellets (spheres) has been achieved; and (iv) removing the smallest and largest particles and dividing the remaining pellets into dosage batches. A novel pharmaceutical composition containing a dosage of 300-500 mg of pellets is obtainable from this process.
Patent JP-3143476-B2 (JP)
IPC: G01B13/24
Filed: 1996-10-21
Granted: 2001-03-07
Abstract: A device for detecting deformations in solids includes a casing constructed and arranged to be insertable in a solid. The casing has walls defining a substantially closed container. The container has an inner dividing wall separating the container into an upper enclosed section and a lower enclosed section. A fluid substantially fills the lower enclosed section and is in fluid communication with the interior walls of the lower enclosed section. A first strain-sensing system is in fluid communication with the lower enclosed section of the container such that deformation of the walls causing pressure changes in the fluid are detected by the first strain-sensing system. A second strain-sensing system is disposed in the upper enclosed section. The upper enclosed section is at least partially filled with fluid. A valve fluidly couples the second strain-sensing system to the lower enclosed section. The valve is operatively associated with the first strain-sensing system and is normally closed, preventing fluid in the lower section from communicating with the second strain-sensing system. The valve is constructed and arranged to open in response to a signal sent from the first strain-sensing system when the first strain-sensing system reaches an operating limit of strain measurement, thereby protecting the first strain-sensing system from being damaged from strains exceeding the operating limit thereof. The second strain-sensing system is constructed and arranged to measure the excessive strains.
Patent JP-2935573-B2 (JP)
IPC: C07D239/60
Filed: 1994-12-20
Granted: 1999-08-16
Abstract: PCT No. PCT/KR94/00178 Sec. 371 Date Jun. 18, 1996 Sec. 102(e) Date Jun. 18, 1996 PCT Filed Dec. 20, 1994 PCT Pub. No. WO95/18109 PCT Pub. Date Jul. 6, 1995Novel 2,4-pyrimidinedione compounds, and pharmaceutically acceptable salts thereof which possess good antiviral activities, and specifically represented by the following formula(I):    <IMAGE>  (I)  wherein: R1 represents an unsubstituted or substituted allyl group represented by CH2CH=CR5R6 or an unsubstituted or substituted propargyl group represented by CH2C 3BOND CR7 wherein R5, R6 and R7 are each independently a hydrogen atom; a methyl group optionally substituted with a halogen atom, or a C1-10 carbonyloxy, hydroxy, azido, cyano, optionally substituted amino, optionally substituted phosphonyl, optionally substituted phenyl, C3-10 heteroaryl, C1-3 alkoxy or benzyloxy radical; a C2-10 alkyl or alkenyl group; a cyclopropyl group; an optionally substituted phenyl group; a C3-10 heteroaryl group; a C1-10 ester group; or an optionally substituted C1-10 alkylamide group; R2 represents a halogen atom, an optionally substituted C1-5 alkyl, C3-6 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl group or a benzyl group; R3 and R4 represent independently a hydrogen or halogen atom, or a hydroxy, C1-3 alkyl, fluoromethyl, C1-3 alkoxy, amino, C2-6 alkylester or C2-7 alkylamide group; A represents an oxygen or sulfur atom; Z represents an oxygen or sulfur atom; a carbonyl group; an amino group; or a methylene group optionally substituted with at least one selected from the group consisting of a halogen atom, and a cyano, hydroxy, azido, amino, C1-3 alkylamide, C1-4 ester, and nitro groups.
Patent JP-2825659-B2 (JP)
IPC: A61K31/425
Filed: 1994-05-19
Granted: 1998-11-18
Abstract: PCT No. PCT/IB94/00113 Sec. 371 Date Jan. 11, 1996 Sec. 102(e) Date Jan. 11, 1996 PCT Filed May 19, 1994 PCT Pub. No. WO95/05378 PCT Pub. Date Feb. 23, 1995Compounds of formula (I) are active antiviral compounds useful in the treatment of viral infections in mammals. The compounds of the invention are readily prepared by reaction of a suitable 2-thiothiazole derivative with an appropriate Het-(CH2)n-halide.
Patent JP-3411036-B2 (JP)
IPC: C07C69/94
Filed: 1994-04-12
Granted: 2003-05-26
Abstract: A process for regioselectively producing a lignan compound of general formula (I) by reacting a lactone compound of general formula (II) with a compound of the formula: R<7>Cl (R<7> being a tri(lower alkyl)silyl group) in the presence of a base, effecting the addition reaction of an acetylene compound of general formula (III) with the resultant compound, and reducing the product. In said formulas R<1> represents alkyl, cycloalkyl, cycloalkyl-lower alkyl, aralkyl, etc.: R<2> and R<3> each represent lower alkoxy, etc.; R<4> represents lower alkoxy or hydrogen; and R<5> and R<6> each represent lower alkyl. <CHEM>
Patent JP-2539342-B2 (JP)
IPC: B29B9/06
Filed: 1994-03-30
Granted: 1996-10-02
Abstract: PCT No. PCT/EP94/01007 Sec. 371 Date Feb. 15, 1995 Sec. 102(e) Date Feb. 15, 1995 PCT Filed Mar. 3, 1994 PCT Pub. No. WO94/25239 PCT Pub. Date Nov. 10, 1994A process for the simultaneous drying and crystallization of crystallizable thermoplastic synthetic material (plastic), e.g. polyethylene terephthalate, in which plastic from the melt is extruded in cord form, solidified at the surface by quenching in water and crystallized by gas treatment and dried, using a device for cooling and drying the cord emerging from dies having a casting gutter with its acceptance end arranged beneath the dies and a device producing a flow of coolant on the casting gutter within a quenching section, a subsequent dewatering section in which the casting gutter has apertures for the free flow of the coolant, a subsequent drying section in which the casting gutter has closely spaced nozzles for the passage of gas and a granulator downstream of the drying section. The lengths of the quenching, dewatering and drying sections must be such, taking account of the rate of creep of the cord along the casting gutter, that the passage time in the quenching section is a maximum of some 1.5 seconds to attain a cord surface temperature of at least 100 DEG  C., in the dewatering section at most some 0.1 second and in the drying section at most about 20 seconds for crystallization, with the surface temperature at the end of the quenching section largely maintained.
Patent JP-5008784-B2 (JP)
IPC: C12N15/09
Filed: 1997-12-17
Granted: 2012-08-22
Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting combination and selection. Compositions produced by these methods are also disclosed.
Patent JP-3563410-B2 (JP)
IPC: H04B10/079
Filed: 1997-01-22
Granted: 2004-09-08
Abstract: The invention is directed to a failure detection system and method for detecting malfunction of an optical amplifier module with one or multiple transmission channels. The failure detection system comprises a unit for measuring a performance parameter of the module; a unit for providing an expected performance parameter; and a comparator unit for receiving the performance parameter and the expected performance parameter and producing an error signal when the performance parameter substantially departs from the expected performance parameter. The system also includes a display/alarm unit for receiving the error signal and accordingly signaling failure of the module. The performance parameter is an output value of the module; a correspondence between an output value and an input value for a transmission channel; a figure of merit (FOMt=t); a set of gains (g) for all transmission channels; and the dynamic range of the amplifier module.
Patent JP-3706144-B2 (JP)
IPC: H04L69/40
Filed: 1997-03-21
Granted: 2005-10-12
Abstract: A protocol interface gateway connects a telecommunication system emulator to a communications network. The gateway receives signals from the network and sends signals to the network that are formatted in a network protocol. The gateway converts signals received from the network into instructions in emulator code, and sends the instructions in emulator code to the emulator for processing. The emulator executes code in blocks of application software utilized in a target telecommunications node. The gateway then receives the processed instructions in emulator code from the emulator, converts the processed instructions into signals formatted in the network protocol, and sends the signals to the communications network. The protocol interface gateway utilizes a UNIX socket that replaces Open Systems Interconnection (OSI) layers 1 and 2 of the network protocol to send and receive the signals from the network.
Patent ES-2568692-B2 (ES)
Title: Bancada de soporte multifunción para cubiertas planas
Inventor: GIL LOPEZ TOMÁS
IPC: H02S20/22
Filed: 2014-10-29
Granted: 2016-09-08
Abstract: Bancada de soporte multifunción para cubiertas planas.#La invención consiste en un soporte tipo bancada para todo tipo de objetos, cuya ubicación son las azoteas de edificios, y está formado por cajones que se unen para adoptar la forma más conveniente en función del dispositivo a soportar, sin necesidad de elementos de anclaje a la cubierta. El soporte en su conjunto puede adaptarse a las distintas inclinaciones de la cubierta y puede combinarse en diversas formas y tamaños.#Por lo tanto, el soporte que constituye la bancada de la invención no tiene que atornillarse ni anclarse al suelo de la cubierta. Se evita el anclaje rellenando el soporte con cualquier elemento pesado. Entre las ventajas está que se evita perforar la lámina impermeable de la cubierta y se facilita su movilidad en caso necesario.
Patent AU-2001266079-B2 (AU)
Title: Azaindole derivatives, process for their preparation, and their use as antitumor agents
Inventor: PITTALA VALERIA
IPC: A61P35/00
Filed: 2001-06-13
Granted: 2006-08-24
Abstract: Novel 1H-pyrrolo[2,3-b]pyridines which are represented by formula (I):wherein R is a hydrogen or halogen atom or a group selected from -CN, -OH, -OCOR4, -(CH2)nNH2, -(CH2)nNHR4, -(CH2)nNHCOR4, -(CH2)nNHCONR4R5, -(CH2)nNHCOOR4, or -(CH2)nNHSO2R4, wherein n is either 0 or 1, R4 and R5 are as described in the specification; R1 is hydrogen or an optionally substituted alkyl group; R2 is an optionally substituted group selected from alkyl or aryl; R3 is hydrogen or a group selected from -CONR4R5, -COOR4, -CONHOR4, -SO2NHR4, alkylsulphonylaminocarbonyl or perfluorinated alkylsulphonylaminocarbonyl; or a pharmaceutically acceptable salt thereof, are disclosed. These compounds are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.
Patent AU-2001285449-B2 (AU)
Title: Quinazoline derivatives as kinase inhibitors
Inventor: MATSUNO KENJI
IPC: C07D403/12
Filed: 2001-08-17
Granted: 2007-04-05
Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinase and treating disese states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
Patent AU-2002223743-B2 (AU)
Title: Means for detecting pathological transformation of the APP protein and their uses
Inventor: VANUXEEM DOROTHEE
IPC: G01N27/447
Filed: 2001-11-05
Granted: 2007-01-11
Abstract: Pathological modifications of the APP protein can be detected in a sample by use of markers consisting of catabolic and/or metabolic fragments of the carboxyl-terminal part of the APP (APP-Cter fragments) resulting from a neurodegenerative condition wherein the APP participates in the etiology. Methods for detecting such markers provide diagnostic and therapeutic applications in degenerative pathologies such as Alzheimer's Disease.
Patent AU-2002227291-B2 (AU)
Title: Compact fuel processor for producing a hydrogen rich gas
Inventor: WOLFENBARGER JAMES K
IPC: C10J1/207
Filed: 2001-12-05
Granted: 2007-08-30
Abstract: A reactor module for use in a compact fuel processor, comprising: 
a catalyst bed; a cooling coil positioned substantially within the catalyst bed for removing excess heat during normal operation; and an electrical heating element positioned within the cooling coil, the heating element capable of heating the catalyst to a desired reaction temperature.
Patent AU-2002301395-B2 (AU)
Title: Cap assembly and optical fiber cooling process
Inventor: PROPSNER PAUL A
IPC: C03B37/027
Filed: 2002-10-09
Granted: 2008-12-04
Abstract: In the cooling of glass fibers there is used a heat exchanger 2 having at least one cap assembly associated therewith. The cap assembly is used for feeding cooling gas to the heat exchanger 2, or for collecting spent cooling gas from the heat exchanger 2, or for supplying a sealing gas to prevent the ingress of atmospheric air into the heat exchanger. The cap assembly has a fiber inlet end 5 with a central opening 7 and a fiber outlet end 6 with a central opening 9. The end 6 is connected by means 11 with a central opening 12 to he heat exchanger 2.l The side walls 4 of the cap assembly have mounted therein part means 8 to allow gas to flow through the side walls 4. The part means 8 comprises at least one hollow bore extending radially out from the side walls 4. The cap assembly is shaped and sized to be removable from the heat exchanger 2. <IMAGE>
Patent AU-2002315060-B2 (AU)
Title: Diagnosing tumorigenicity and determining resistance to anticancer therapy
Inventor: SERRERO GINETTE
IPC: A61K38/00
Filed: 2002-06-14
Granted: 2007-07-12
Abstract: Methods and kits for diagnosing tumorigenicity and for determining whether a cancer patient is resistant to the pharmacological effects of antiestrogen therapy. Increased levels of the PCDGF (GP88) growth factor are indicative of tumorigenicity and resistance to the pharmacological effects of antiestrogen therapy. The methods and kits of the invention are useful for assessing the tumorigencity of a biological sample from a patient and determining whether the patient is a candidate for antiestrogen, including tamoxifen, therapy.
Patent AU-2002333837-B2 (AU)
Title: Edible emulsion spread
Inventor: PELAN EDWARD G
IPC: A23D7/02
Filed: 2002-09-13
Granted: 2005-10-27
Abstract: Edible W/O-emulsion spread, which spread possesses ambient emulsion stability in the absence of partial glycerides, which spread comprises a dispersed aqueous phase which contains at least X wt. % on aqueous phase of a natural thickening agent, preferably a natural stach, which agent is characterized by a peak value in the temperature related viscosity graph of an aqueous dispersion of the thickener and where the thickener concentration X is chosen such that an aqueous dispersion with that concentration has a peak viscosity which is at least 70 Brabender Units and an end viscosity which preferably is at least 60 Brabender Units. The found aqueous phase ensures that a reduced (25-40 wt. %) fat emulsion spread, without the addition of partial glycerides, remains stable at an ambient temperature of 15° C. for at least seven days.
Patent AU-2003217728-B2 (AU)
Title: N-Biphenylmethyl aminocycloalkanecarboxamide derivatives
Inventor: ANTHONY NEVILLE J
IPC: C07C233/50
Filed: 2003-02-04
Granted: 2008-11-20
Abstract: N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.